Table 4.

Progression of renal impairment determined as annualized rate of change in eGFR in male and female patients stratified by baseline eGFR and urinary protein levels.

	FOS Evaluable Treated Renal cohort		Schiffmann et al. (untreated) [21]
	Mean annualized eGFR slope (SEM) [95% CI],a mL/min/1.73 m2/y
Subgroup	n		n
Baseline eGFR category (mL/min/1.73 m2)
Males
≥ 60	117	− 1.68 (0.19) [− 2.05, − 1.31]	117	− 3.0 (0.1)
< 60	18	− 2.86 (0.53) [− 3.90, − 1.83]	28	− 6.8 (1.5)
Females
≥ 60	111	− 0.43 (0.21) [− 0.83, − 0.02]	42	− 0.9 (0.9)
< 60	22	0.36 (0.42) [− 0.47, 1.19]	13	− 2.1 (1.6)
Baseline urinary protein level category (g/24 h)
Males
≥ 1.0	16	− 4.76 (0.56) [− 5.85, − 3.66]	22	− 6.9 (1.5)
0.1 to 1.0	74	− 1.62 (0.23) [− 2.08, − 1.17]	21	− 3.3 (1.8)
< 0.1	15	− 1.32 (0.48) [− 2.26, − 0.38]	18	− 1.6 (1.5)
Females
≥ 1.0	17	− 0.41 (0.51) [− 1.42, 0.59]	5	− 4.6 (2.3)
0.1 to 1.0	70	− 0.44 (0.26) [− 0.95, 0.07]	17	− 2.2 (2.2)
< 0.1	22	− 0.16 (0.42) [− 0.97, 0.66]	7	− 0.6 (2.6)

CI, confidence interval; eGFR, estimated glomerular filtration rate; FOS, Fabry Outcome Survey; SEM, standard error of the mean.

^aMedian (range) number of assessments for males and females: Schiffmann et al., 6 (3 to 33); FOS, 10 (3 to 70).